

Cite this: *RSC Adv.*, 2018, 8, 21786Received 1st May 2018  
Accepted 2nd June 2018

DOI: 10.1039/c8ra03732a

rsc.li/rsc-advances

# Highly efficient green synthesis and photodynamic therapeutic study of hypericin and its derivatives†

Ying Zhang, Kun Shang, Xiaowen Wu, Siyu Song, Zebo Li, Zhichao Pei and Yuxin Pei \*

A highly efficient synthetic pathway for hypericin (**7a**) was achieved under mild conditions with an overall yield over two steps of 92% using emodinanthrone as a starting material, where protohypericin, a key precursor of hypericin, was synthesized in water with microwave assistance, which was then photocyclized to hypericin with a high yield *via* 1 h irradiation in a visible light reactor equipped with 575 nm monochromatic lamps. In addition, the method could be used to synthesize hypericin derivatives (**7b–d**) with similar overall yields. Furthermore, their effects of photodynamic therapy (PDT) were evaluated on A431, HepG-2, and MCF-7 cell lines. The PDT of **7b** was better than that of **7a**, whereas **7c** and **7d** were worse. Unlike other cell lines, MCF-7 was not sensitive to any of **7a–d** at the same concentrations.

## Introduction

Hypericin is a natural polycyclic aromatic dianthraquinone present in the St. John's Wort plant (*Hypericum perforatum*).<sup>1</sup> It has been used as a traditional herbal medicine since ancient times for its anti-viral, anti-bacterial, and anti-inflammatory properties as well as to treat depression.<sup>2–7</sup> In recent years, it has attracted increasing interest due to its potential as an effective photosensitizer used in photodynamic therapy (PDT) to fight various cancers.<sup>8–10</sup>

The isolation of pure hypericin from *Hypericum perforatum* is a tedious procedure due to its very low content in the plant (0.03 to 0.09%)<sup>11</sup> and poor solubility in solvents.<sup>1</sup> To meet the needs of hypericin demand both from academic and industrial areas, great efforts have been made in the past to develop a way for it to be chemically synthesized. The first step towards the successful chemical synthesis of hypericin dates back to 1957, when Brockmann and his co-workers for the first time reported a total synthetic pathway of hypericin. Their pathway started from 3,5-dimethoxybenzoic acid methyl ester and involved 12 steps in total that resulted in a low overall yield of hypericin of 6% to 9%.<sup>12</sup> Other total synthetic methods that were later developed started with ethyl formate, chlorinated ketene or 2-methyl anthraquinone, and shortened the synthetic pathway to 6 to 8 steps, although none of these methods reached an overall yield that was higher than 10%.<sup>6,13–15</sup> In addition, these methods were generally characterized by the usage of extremely high


temperature, pressure and as having a very long reaction time (up to 10 days). Besides the total synthesis, semi-synthesis of hypericin was proposed by Falk and coworkers using emodin extracted from Cortex frangulae as the starting material.<sup>1</sup> Falk's method only required 3 steps, where emodin was first reduced to emodinanthrone by SnCl<sub>2</sub> in concentrated HCl with a high yield of 90%, and then emodinanthrone took place oxidative dimerization in pyridine to form protohypericin, which was finally photocyclized to hypericin upon irradiation of visible light overnight in a moderate yield of 56% (overall yield was 51.6%). Although the overall yield was later increased to 74% by the same group by introducing microwave assistance in the synthesis of protohypericin, the reaction was carried out in a toxic organic solvent DMF and in the presence of a corrosively organic base potassium *t*-butoxide.<sup>16</sup> Additionally, the photocyclization step of protohypericin to hypericin took place overnight with a 500 W halogen lamp.<sup>17</sup> Therefore, it is necessary to find an efficient pathway for the synthesis of hypericin, where the required reactions can be performed under mild conditions, the solvents involved in each step are less or non-toxic, easy to handle after the reactions, and would preferably be water based to comply with the standpoints of green chemistry.

In this paper, as shown in Scheme 1, a greatly more efficient, facile and environmentally friendly method for the synthesis of hypericin (**7a**) was developed. This method started with the easily available emodinanthraquinone, from where its precursor protohypericin was obtained in water by using microwaves and the irradiation of protohypericin in acetone with 575 nm visible light. This method resulted in a high hypericin overall yield. Furthermore, we delightedly found that the strategy could be successfully adapted for the synthesis of the derivatives of hypericin (**7b–d**), which are especially

Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling, Shaanxi 712100, PR China. E-mail: peiyx@nwfufu.edu.cn

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c8ra03732a





**Scheme 1** General synthetic pathway of hypericin (**7a**) and its derivatives (**7b–d**). Reagents and conditions: (1) 1.5% NaOH/H<sub>2</sub>O, pyridine-*N*-oxide, FeSO<sub>4</sub>·7H<sub>2</sub>O, 105 °C, 10 W, 70 min, N<sub>2</sub> by microwave reactor; (2) 575 nm monochromatic light, acetone, N<sub>2</sub>, 60 min.

significant in new photosensitizer discovery<sup>18,19</sup> used in cancer photodynamic therapy.

## Experimental

### General remarks

All reagents and solvents were purchased from commercial suppliers and used without further purification unless specified. Dimethyl sulfate, *N*-bromosuccinimide (NBS), 18-crown-6 and benzoyl peroxide (BPO) were purchased from Energy Chemical Reagent Co. Triphenyl phosphine and tin(II) chloride dehydrate (SnCl<sub>2</sub>·2H<sub>2</sub>O) were purchased from Sinopharm Chemical Reagent Co. Butyraldehyde was purchased from TCI. Benzaldehyde was purchased from Aladdin. Ferrous sulfate heptahydrate (FeSO<sub>4</sub>·7H<sub>2</sub>O) was purchased from Tianjin Bodi Chemical Co., Ltd. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Kehao Biotech Co., Ltd. Flash chromatography was performed using silica gel with a grain size of 40–63 μm (Qingdao Haiyang Co., Ltd). RPMI 1640 medium, Dulbecco's Modified Essential Medium (DMEM) and trypsin–EDTA solution were obtained from Gibco BRL Co., Ltd. Penicillin/streptomycin was purchased from Nanjing KeyGen Biotech, fetal bovine serum was purchased from Yuanhengjinma Co., Ltd.

<sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker 500 MHz Spectrometer with working frequencies of 500 MHz for <sup>1</sup>H and 125 MHz for <sup>13</sup>C, respectively, in DMSO-*d*<sub>6</sub>, MeOH-*d*<sub>4</sub> or CDCl<sub>3</sub>. The residual signals from DMSO-*d*<sub>6</sub> (<sup>1</sup>H: δ 2.50 ppm; <sup>13</sup>C: δ 39.52 ppm), or MeOH-*d*<sub>4</sub> (<sup>1</sup>H: δ 3.31 ppm; <sup>13</sup>C: δ 49.00 ppm), CDCl<sub>3</sub> (<sup>1</sup>H: δ 7.26 ppm; <sup>13</sup>C: δ 77.00 ppm) were used as internal standards. HRMS (High Resolution Mass Spectrometer) analysis was performed on Agilent 1290-6540 UHPLC Q-TOF-HRMS. Microwave assisted syntheses were performed with Discover SP (USA). Photochemical reaction was performed with a Rayonet Chamber Reactor (Model RPR-100) equipped with 16 of 575 nm monochromatic lamps (25 W per lamp, 400 W in total, USA). The UV-Vis spectra were recorded with a Shimadzu 1750 UV-Visible spectrophotometer (Japan) at 298 K. The melting points were measured by a WRS-2 melting point apparatus (Shanghai, China) with a range of room temperature to 300 °C. The compounds **4**, **12**, **14** were prepared according to the published procedures<sup>20,21</sup> (details can be found in ESI†).

**1,3,8-Trihydroxy-6-methylanthracen-9(10*H*)-one (5a).** Compound **5a** was synthesized by following a published procedure.<sup>22</sup> To a 250 mL flask, emodin (1.36 g, 5.0 mmol) was stirred in 100 mL glacial acetic acid (98%) at 60 °C. Then SnCl<sub>2</sub>·2H<sub>2</sub>O (7.9 g, 35 mmol) dissolved in 50 mL concentrated hydrochloric acid was added dropwise into the flask. Then this resulting solution was refluxed for 2 h, which was then poured into ice water. The precipitate formed was filtered, washed with deionized water, and then vacuum dried. The crude was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 4 : 1, v/v) to give **5a** as a pale yellow solid (1.22 g, 96%). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.37 (s, 1H), 12.21 (s, 1H), 10.82 (s, 1H), 6.77 (s, 1H), 6.67 (s, 1H), 6.42 (s, 1H), 6.22 (d, *J* = 4.3 Hz, 1H), 4.29 (s, 2H), 2.32 (s, 3H) ppm.<sup>23</sup>

**4,5,7-Trihydroxy-10-oxo-9,10-dihydroanthracene-2-carboxylic acid (5b).** Compound **5b** was synthesized by following a published procedure.<sup>22</sup> To a 50 mL flask, compound **4** (300 mg, 1.0 mmol) was dissolved in 20 mL glacial acetic acid at 60 °C. To this solution, SnCl<sub>2</sub>·2H<sub>2</sub>O (1.59 g, 7.0 mmol) dissolved in 11 mL concentrated hydrochloric acid was added drop wise. Then this resulting solution was refluxed for 2 h, which was then poured into ice water. The precipitate formed was filtered, washed with deionized water, and vacuum dried. The crude was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 4 : 1, v/v) to give **5b** as a pale yellow solid (0.3 g, 92%). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 13.24 (br, 1H), 12.29 (s, 1H), 12.22 (s, 1H), 10.99 (s, 1H), 7.46 (s, 1H), 7.27 (s, 1H), 6.445–6.439 (m, 1H), 6.25 (d, *J* = 2.7 Hz, 1H), 4.42 (s, 2H) ppm.<sup>24</sup>

**1,3,8-Trihydroxy-6-pentylanthracen-9(10*H*)-one (5c).** Compound **5c** was synthesized by following a published procedure with modification.<sup>22</sup> To a 25 mL flask, **12** (55.6 mg, 0.15 mmol) was dissolved in 7 mL glacial acetic acid. To this solution, SnCl<sub>2</sub>·2H<sub>2</sub>O (270 mg, 1.2 mmol) dissolved in 4 mL 33% HBr was added drop wise. After being refluxed for 1.5 h, the reaction mixture was then poured into ice water. The precipitate formed was filtered, washed with deionized water, and vacuum dried. The crude product was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 6 : 1, v/v) to give **5c** as a pale yellow solid (33.6 mg, 71%). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>) δ 12.37 (s, 1H), 12.20 (s, 1H), 10.81 (s, 1H), 6.77 (s, 1H), 6.66 (s, 1H), 6.41 (d, *J* = 1.3 Hz, 1H), 6.23 (d, *J* = 2.2 Hz, 1H), 4.29 (s, 2H), 2.55 (t, *J* = 7.45 Hz, 2H), 1.60–1.54 (m, 2H), 1.34–1.23 (m, 4H), 0.86 (t, *J* = 7.0 Hz, 3H) ppm; <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>) δ 191.0, 165.0, 164.5, 161.7, 151.7, 145.0, 141.9, 119.1, 114.4, 113.0, 108.4, 107.3, 100.9, 35.4, 32.3, 30.9, 29.8, 21.9, 13.9 ppm. HRMS: *m/z* calcd for C<sub>19</sub>H<sub>20</sub>O<sub>4</sub> [M + H]<sup>+</sup> 313.1440, found 313.1439. M.p.: 161.4–162.0 °C.

**1,3,8-Trihydroxy-6-phenylanthracen-9(10*H*)-one (5d).** Compound **5d** was synthesized by following a published procedure with modification.<sup>22</sup> To a 100 mL flask, **14** (40 mg, 0.85 mmol) was dissolved in 30 mL acetic acid. To this resulting solution, SnCl<sub>2</sub>·2H<sub>2</sub>O (1.53 g, 6.8 mmol) dissolved in 20 mL 33% HBr was added drop wise. After being refluxed for 1.5 h, the reaction mixture was then poured into 50 mL ice water. The precipitate formed was filtered, washed with deionized water, and vacuum dried. The crude was purified by flash column chromatography (eluent: petroleum ether/ethyl acetate = 6 : 1, v/v) to give **5d** as a pale yellow solid (265 mg, 90%). <sup>1</sup>H NMR (500



MHz, DMSO- $d_6$ )  $\delta$  12.37 (s, 1H), 12.21 (s, 1H), 10.85 (s, 1H), 7.30–7.23 (m, 4H), 7.20–7.15 (m, 1H), 6.85 (s, 1H), 6.74 (s, 1H), 6.43 (d,  $J = 1.2$  Hz, 1H), 6.22 (d,  $J = 2.1$  Hz, 1H), 4.30 (s, 2H), 2.93–2.85 (m, 4H) ppm.  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ )  $\delta$  191.1, 165.0, 164.6, 161.7, 150.7, 145.0, 142.0, 141.2, 128.4, 128.3, 126.0, 119.3, 114.6, 113.2, 108.4, 107.4, 101.0, 37.2, 36.0, 32.4 ppm. HRMS:  $m/z$  calcd for  $\text{C}_{22}\text{H}_{18}\text{O}_4$   $[\text{M} + \text{H}]^+$  347.1283, found 347.1281. M.p.: 196.7–197.1 °C.

### General procedure for the synthesis of protohypericin and its derivatives

To a microwave 10 mL tube, **5a**, **5b**, **5c**, or **5d** (0.5 mmol, 1 equiv.), pyridine-*N*-oxide (2.5 mmol, 5 equiv.),  $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$  (10 mg, 36  $\mu\text{mol}$ ), and NaOH (40 mg, 1.0 mmol) were dissolved in 2 mL ultrapure water. The mixture was placed in a microwave reactor at 10 W, 105 °C under argon atmosphere for 70 min. The reaction mixture was then cooled to room temperature, and was acidified with 3% hydrochloric acid. The precipitate was filtered, washed with deionized water, and vacuum dried. The purification with column chromatography on silica gel by using petroleum ether/ethyl acetate/methanol (4 : 8 : 1, v/v/v) as eluent gave **6a–d**, respectively.

**Protohypericin (6a)**. Purple solid (122 mg, 96%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$ : 14.36 (br, 2H), 12.86 (br, 2H), 7.20 (s, 2H), 6.74 (s, 2H), 6.33 (s, 2H), 2.05 (s, 6H) ppm.<sup>25</sup>

**1,3,4,6,8,15-Hexahydroxy-7,16-dioxo-7,16-dihydrodibenzo[*a,o*]perylene-10,13-dicarboxylic acid (6b)**. Purple solid (270 mg, 96%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  14.69 (s, 2H), 14.47 (s, 2H), 7.77 (s, 2H), 7.73–7.69 (m, 1H), 7.68–7.63 (m, 1H), 6.62 (s, 2H) ppm.<sup>25</sup>

**1,3,4,6,8,15-Hexahydroxy-10,13-dipentylidibenzo[*a,o*]perylene-7,16-dione (6c)**. Purple solid (140 mg, 90%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  14.37 (s, 2H), 12.84 (s, 2H), 7.19 (s, 2H), 6.73 (s, 2H), 6.33 (s, 2H), 2.39–2.21 (m, 4H), 1.38–1.07 (m, 12H), 0.80 (t,  $J = 6.9$  Hz, 6H) ppm.  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ )  $\delta$  184.4, 174.0, 168.3, 160.0, 147.5, 136.4, 129.8, 127.9, 125.3, 119.6, 115.4, 113.5, 104.2, 99.7, 35.3, 30.8, 29.6, 21.8, 13.6 ppm. HRMS:  $m/z$  calcd for  $\text{C}_{38}\text{H}_{34}\text{O}_8$   $[\text{M} - \text{H}]^-$ , 617.2176, found: 617.2171. M.p. > 300 °C.<sup>24</sup>

**10,13-Dibenzyl-1,3,4,6,8,15-hexahydroxydibenzo[*a,o*]perylene-7,16-dione (6d)**. Purple solid (97 mg, 94%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  14.40 (s, 2H), 12.89 (s, 2H), 7.33 (s, 2H), 7.24–7.18 (m, 4H), 7.16–7.04 (m, 6H), 6.82 (s, 2H), 6.36 (s, 2H), 2.70–2.54 (m, 8H) ppm.  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ )  $\delta$  184.1, 174.3, 168.0, 162.1, 147.5, 139.9, 127.6, 127.5, 127.2, 125.5, 125.1, 121.6, 120.4, 119.0, 117.9, 108.6, 105.7, 102.3, 21.2, 18.7 ppm. HRMS:  $m/z$  calcd for  $\text{C}_{44}\text{H}_{30}\text{O}_8$   $[\text{M} - \text{H}]^-$ , 685.1863, found: 685.1871. M.p. > 300 °C.

### General procedure for the synthesis of hypericin and its derivatives

To a 50 mL flask, **6a**, **6b**, **6c**, or **6d** (0.25 mmol, 1.0 equiv.) dissolved in 20 mL acetone was irradiated for 60 min by means of 575 nm monochromatic lamps. The color of the mixture changed from hyacinthine to prunosus. The solvent was removed under vacuum. The crude was purified by flash

chromatography on silica gel by using petroleum ether/ethyl acetate/methanol (2 : 8 : 0.5, v/v/v) as eluent to give respective **7a–d**.

**Hypericin (7a)**. Purple solid (122 mg, 96%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  14.66 (s, 2H), 14.03 (s, 2H), 7.31 (s, 2H), 6.44 (s, 2H), 2.65 (s, 6H) ppm.<sup>25</sup>

**1,6,8,10,11,13-Hexahydroxy-7,14-dioxo-7,14-dihydrophenanthro[1,10,9,8-opqra]perylene-3,4-dicarboxylic acid (7b)**. Purple solid (135 mg, 96%).  $^1\text{H}$  NMR (500 MHz, DMSO- $d_6$ )  $\delta$  14.73 (s, 2H), 14.11 (s, 2H), 7.51 (s, 2H), 6.61 (s, 2H) ppm.<sup>24</sup>

**1,3,4,6,8,13-Hexahydroxy-10,11-dipentylphenanthro[1,10,9,8-opqra]perylene-7,14-dione (7c)**. Purple solid (144 mg, 94%).  $^1\text{H}$  NMR (500 MHz, MeOD)  $\delta$  7.24 (s, 2H), 6.69 (s, 2H), 1.40–1.12 (m, 6H), 1.08–0.94 (m, 2H), 0.93–0.80 (m, 4H), 0.74–0.61 (m, 6H), 0.47 (t,  $J = 7.2$  Hz, 6H) ppm.  $^{13}\text{C}$  NMR (125 MHz, DMSO- $d_6$ )  $\delta$  191.5, 165.4, 165.0, 162.2, 152.1, 145.4, 142.4, 119.6, 114.9, 113.5, 108.9, 107.8, 101.4, 40.5, 40.3, 40.2, 40.0, 39.8, 39.7, 39.5, 35.8, 32.8, 31.4, 30.3, 22.4, 14.4 ppm. HRMS:  $m/z$  calcd for  $\text{C}_{38}\text{H}_{32}\text{O}_8$   $[\text{M} + \text{H}]^+$ , 617.2175, found: 617.2176. M.p. > 300 °C.

**3,4-Dibenzyl-1,6,8,10,11,13-hexahydroxyphenanthro[1,10,9,8-opqra]perylene-7,14-dione (7d)**. Purple solid (160.6 mg, 94%).  $^1\text{H}$  NMR (500 MHz, MeOD)  $\delta$  7.34 (s, 2H), 6.75 (s, 2H), 6.35–6.21 (m, 6H), 6.12–6.00 (m, 4H), 3.80–3.69 (m, 2H), 3.54–3.45 (m, 2H), 2.76–2.67 (m, 2H), 2.13–2.03 (m, 2H) ppm.  $^{13}\text{C}$  NMR (125 MHz, MeOD)  $\delta$  185.89, 172.4, 167.9, 162.6, 147.1, 139.1, 127.6, 127.0, 126.7, 125.7, 124.4, 121.9, 120.9, 118.1, 117.2, 108.9, 105.6, 103.1, 39.0, 38.9 ppm. HRMS:  $m/z$  calcd for  $\text{C}_{44}\text{H}_{28}\text{O}_8$   $[\text{M} + \text{H}]^+$ , 685.1857, found: 685.1858. M.p. > 300 °C.

### Cell culture

The breast cancer cell line (MCF-7), human hepatoma cell line (HepG-2) and the human skin basal cell carcinoma (A431) were obtained from American Type Culture Collection. MCF-7 and A431 cells were cultured at 37 °C under a humidified 5%  $\text{CO}_2$  in DMEM (Dulbecco's Modified Eagle Medium) medium supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin; and HepG-2 cells were cultured in the same way except the culture medium used was RPMI 1640.

### Cell viability assay

The relative cell viability of compound **7a** (**7b**, **7c**, or **7d**) was evaluated *in vitro* by MTT assay. HepG-2, MCF-7 or A431 cells were seeded respectively in 96-well plates at a density of  $5 \times 10^3$  cells per well in 100  $\mu\text{L}$  RPMI 1640 or DMEM medium, and grew for 24 h at 37 °C. Then the medium was replaced by 90  $\mu\text{L}$  fresh medium and 10  $\mu\text{L}$  **7a** (**7b**, **7c**, or **7d**) in PBS (containing 0.2% DMSO- $d_6$ ) at different concentrations (0.2, 0.4, 0.6, 0.8, 1.0  $\mu\text{M}$ ). After 4 h incubation, the cells were washed with PBS for 3 times, and then fresh medium was added. The cells were exposed to a LED array photosource ( $\lambda = 595\text{--}600$  nm, 8.6 mW  $\text{cm}^{-2}$ ) for 30 min, and further cultured for 24 h at 37 °C. Then 10  $\mu\text{L}$  fresh medium containing MTT (5 mg  $\text{mL}^{-1}$ ) was added to each well. After 4 h incubation, 100  $\mu\text{L}$  DMSO was added to each well to dissolve formazan crystals. Finally, the plate was gently shaken for 10 min and the absorbance at 490 nm was recorded with a microplate reader.



## Results and discussion


### Reaction optimization for synthesis of protohypericin

Protohypericin was the key precursor to the synthesis of hypericin, therefore the dimerization of emodinanthrone leading to protohypericin was recognized as the key step in this method.<sup>16</sup> The synthesis of protohypericin has been extensively studied, which can be summarized in two methods based on starting materials, (1) emodin-type:<sup>20,26</sup> by using potassium hydroxide as a base, protohypericin can be synthesized in the presence of hydroquinone in water. The drawbacks are extremely long reaction time (7–20 days) and low yield (25–72%); (2) emodinanthrone-type:<sup>16,17</sup> by using potassium *t*-butoxide or piperidine as a base, protohypericin can be obtained in a moderate yield (70–78%) in a short time. While the drawbacks here are the requirement of notorious organic solvents (DMF or pyridine) and a still unsatisfying yield. Based on the discoveries previously reported in the literature, we chose emodinanthrone as a starting material for our method in order to pursue the development of an economic, green, and efficient synthetic method of protohypericin. In our method, the dimerization of

emodinanthrone was performed in a microwave reactor by using cheap and easy to handle inorganic bases (such as NaOH, KOH, and LiOH) as a replacement for the organic bases, and water as solvent instead of the organic solvents. The reaction conditions were varied to study their effect on the yield, and the results were summarized in Table 1.

The various parameters, including the amount of pyridine *N*-oxide (PNO), catalyst, FeSO<sub>4</sub>·7H<sub>2</sub>O, base, reaction temperature and time, were thoroughly investigated. As shown in Table 1, the presence of pyridine *N*-oxide (PNO) and a suitable redox catalyst in the reaction were crucial for the reaction, with either absence leading to failure. For example, in the absence of PNO, **6a** was obtained with only 6% yield, which demonstrated that PNO was an indispensable oxygen transfer reagent in this reaction system. While the absence of FeSO<sub>4</sub>·7H<sub>2</sub>O led to no reaction at all.<sup>3</sup> In addition, ferric chloride could be used to substitute FeSO<sub>4</sub>·7H<sub>2</sub>O without compromise of the yield<sup>4</sup> but copper chloride could not.<sup>5</sup> The variation of the amount of PNO did not influence the yield much provided that the other reaction conditions were kept unchanged,<sup>1,7,8</sup> where the best yield of 96% was obtained when PNO was 5 equivalents;<sup>1,11</sup> The

Table 1 Reaction optimization for synthesis of **6a**.



Entry	Reaction conditions					
	PNO (equiv.)	Catalyst (equiv.) <sup>b</sup>	Base	<i>T</i> (°C)	<i>t</i> (min)	Yield <sup>c</sup> (%)
1 <sup>a</sup>	5.0	0.08	1.5% NaOH	105	70	96
2	—	0.08	1.5% NaOH	105	70	6
3	5.0	—	1.5% NaOH	105	70	N.D
4	3.2	0.08 <sup>d</sup>	6.0% NaOH	105	70	94
5	5.2	0.08 <sup>e</sup>	6.0% NaOH	105	70	Very low
6	—	3.0 <sup>d,f</sup>	6.0% NaOH	105	70	N.D
7	3.5	0.08	1.5% NaOH	105	70	93
8	4.5	0.08	1.5% NaOH	105	70	91
9	5.0	0.08	0.5% NaOH	105	70	77
10	5.0	0.08	1.0% NaOH	105	70	94
11	5.0	0.08	2.0% NaOH	105	70	96
12	5.0	0.08	5.0% NaOH	105	70	76
13	5.0	0.08	1.5% LiOH	105	70	71
14	5.0	0.08	3.6% LiOH	105	70	95
15	5.0	0.08	1.5% KOH	105	70	77
16	5.0	0.08	2.1% KOH	105	70	93
17	5.0	0.08	1.5% NaOH	90	70	72
18	5.0	0.08	1.5% NaOH	100	70	90
19	5.0	0.08	1.5% NaOH	120	70	88
20	5.0	0.08	1.5% NaOH	105	50	86
21	5.0	0.08	1.5% NaOH	105	60	90
22	5.0	0.08	1.5% NaOH	105	80	89
23	5.0	0.08	1.5% NaOH	105	90	90

<sup>a</sup> The optimized conditions: **5a**, 120 mg, 1 equivalent; microwave, 10 W; water (2 mL); N<sub>2</sub> atmosphere. <sup>b</sup> The catalyst was FeSO<sub>4</sub>·7H<sub>2</sub>O unless specified. <sup>c</sup> Isolated yield. N.D: no detection. <sup>d</sup> The catalyst was FeCl<sub>3</sub>. <sup>e</sup> The catalyst was CuCl<sub>2</sub>. <sup>f</sup> O<sub>2</sub> atmosphere.






Fig. 1 (a) UV-Vis absorption spectra of **6a** and **7a** (0.04 M in acetone); (b) emission spectrum of the monochromatic lamp with a maximum peak at 575 nm.

base, such as NaOH, helps to dissolve emodinanthrone in the reaction mixture and has obvious influence on the yield. A concentration of NaOH lower than 0.5% or higher than 5% decreased the yield from over 90% to about 76%. It's worth to mention that LiOH and KOH, which have similar chemical properties as NaOH, gave more or less equally good yields (95% for LiOH<sup>13</sup> and 93% for KOH<sup>15</sup>), although the concentration of the two hydroxides used was slightly higher than that of NaOH. The study on the effect of reaction temperature disclosed that the yield increased with the temperature and reached to a peak value (96% at 105 °C, see Falk *et al.*<sup>1</sup>); further increase of the temperature did not benefited a higher yield, for instance, 88% was obtained at 120 °C.<sup>17</sup> This might be ascribed to the possibility that high temperature led to side reactions, such as the oxidation of hydroxyl groups in emodinanthrone. The screening on reaction time proved that the yield increased with the reaction time<sup>18,19</sup> and reached the best yield of 96% at 70 min.<sup>1</sup> After this point, the yield decreased slightly with the reaction time with about 6%,<sup>20,26</sup> which may due to the decomposition of protohypericin in the hot basic solution.

Notably, the reaction can be carried out in gram-scale with 91.6% yield under the optimized conditions (see ESI†).

### Synthesis of hypericin and its derivatives

It was known that a major method to obtain hypericin was the photocyclization of protohypericin irradiated with visible light. The light sources reported previously include sunlight,<sup>27</sup> halogen,<sup>17</sup> glow,<sup>20</sup> and high-/low-pressure mercury lamps.<sup>1</sup> The

reaction time varied from 10 min claimed by Falk *et al.*<sup>1</sup> to 24 h by Kim *et al.*<sup>20</sup> as well as the yield from 31% to 92%. We speculated the enormous variation of the reaction time and yield might result from the emission difference of the light sources.

The UV-Vis spectra of **6a** and **7a** were shown in Fig. 1a. Considering<sup>20,27,28</sup> protohypericin has a strong absorption band at 525–590 nm while no obvious absorption for **7a** at 575 nm, we chose monochromatic lamps with a maximum emission peak at 575 nm as visible light source (Fig. 1b) to perform the photocyclization of **6a**. The monitoring of the reaction by TLC displayed that the reaction was completed at 1 h, where an isolated yield of 96% was obtained by flash chromatography. The reaction has very good reproducibility and can be performed on large scale with little compromise to the yield (89.8%, see ESI†).

To study the applicability of the synthetic pathway developed above, the derivatives of hypericin with different substituents were synthesized accordingly, where methyl groups on 10- and 11- positions in hypericin (**7a**) were replaced with carboxyl groups for **7b**, pentyl groups for **7c**, and phenethyl groups for **7d**, respectively. As described in Scheme 1, starting with **5b–c**, the analogues of emodinanthrone **5a**, respective **6b–d** were successfully synthesized with satisfying to excellent isolated yields (90–96%) under the optimized conditions screened for **5a**, which were subjected to irradiation of visible light to give corresponding **7b–d** with excellent yields (94–96%). This indicates that the synthetic pathway developed in the present work has good applicability for the derivatives of hypericin, which is significant in photosensitizer discovery based on natural bioactive molecules.

### Photodynamic therapy study

Photodynamic therapy (PDT) is a noninvasive technique that is used to treat and detect small and superficial tumors.<sup>29–34</sup> Hypericin has been regarded as an effective natural photosensitizer,<sup>35–37</sup> and has gained increasing attention as a potential alternative treatment for various cancers due to its unique photochemical properties and photobiological activities.<sup>9,38–41</sup> To explore the potential of the three derivatives **7b–d** as photosensitizer for PDT, A431, HepG-2, and MCF-7 cell lines were used for cell cytotoxicity evaluation at a concentration range of 0.2–1.0 μM with MTT assay. For comparison, hypericin was used as a control. As displayed in Fig. 2, **7b** showed better




Fig. 2 Cell viability of A431 cells (a); HepG2 cells (b); and MCF-7 cells (c) determined by MTT cell viability assay. The cells were incubated with compound **7a–d**, respectively, and irradiated with 595–600 nm light for 30 min.



cytotoxicity to the test cell lines than **7a**, while the cytotoxicity of **7c** and **7d** were much less than that of **7a** at the same concentrations. This may be attributed to the better water solubility of **7b**. The results imply that the properties of the substituents on position of 10- and 11- in hypericin molecules are strongly related to its photocytotoxicity: changing methyl groups to hydrophilic ones (such as  $-\text{COOH}$  for **7b**) can enhance the hydrophilicity of a resulting compound and hence create a better photocytotoxicity; on contrary, the more hydrophobic and steric the substituents, the worse the photocytotoxicity (for instance, comparing methyl groups in **7a** with pentyl in **7c** or phenethyl in **7d**).<sup>10,42–46</sup> These findings are in line with those reported in the literature.<sup>21,40,47</sup>

## Conclusions

In summary, we developed an economic, green and highly efficient synthetic pathway for preparing hypericin and its derivatives under mild reaction conditions. Water was used as the solvent in the key step of emodinanthrone dimerization. The reaction time of the photocyclization of protohypericin was greatly shortened to 1 h. Furthermore, the PDT effect of **7b** is better than those of **7a**, **7c** and **7d**. These results indicate the derivatives of hypericin synthesized in the present work have the potential as photosensitizers for fighting cancers.

## Conflicts of interest

The authors declare no competing financial interest.

## Acknowledgements

This research work was supported by the National Natural Science Foundation of China (21772157, 21572181 and 21174113) to the Project of Science and Technology of Social Development in Shaanxi Province (2016SF-029) and Yangling Demonstration Zone (2016SF-029).

## References

- H. Falk, From the photosensitizer hypericin to the photoreceptor stentorin—the chemistry of phenanthroperylene quinones, *Angew. Chem.*, 1999, **38**, 3117–3136.
- J. Barnes, L. A. Anderson and J. D. Phillipson, St John's Wort (*Hypericum perforatum* L.): a review of its chemistry, pharmacology and clinical properties, *J. Pharm. Pharmacol.*, 2001, **53**, 583–600.
- K. Souvik, L. Marc, Z. Sebastian and S. Michael, An endophytic fungus from *Hypericum perforatum* that produces hypericin, *J. Nat. Prod.*, 2008, **71**, 159–162.
- P. S. Martin, C. Anthony, J. C. Marie, C. D. Jean and N. Michel, Hypericin activates l-type  $\text{Ca}^{2+}$  channels in cardiac myocytes, *J. Nat. Prod.*, 2007, **70**, 510–514.
- K. Souvik, Z. Sebastian, K. Ján, C. Eva and S. Michael, Light-independent metabolomics of endophytic thielavia subthermophila provides insight into microbial hypericin biosynthesis, *J. Nat. Prod.*, 2009, **72**, 1825–1835.
- N. Adolf and B. Veronika, Lessons learned from herbal medicinal products: the example of St. John's Wort, *J. Nat. Prod.*, 2010, **73**, 1015–1021.
- K. Michalska, H. Fernandes, M. Sikorski and M. Jaskolski, Crystal structure of Hyp-1, a St. John's Wort protein implicated in the biosynthesis of hypericin, *J. Struct. Biol.*, 2010, **169**, 161–171.
- A. Kamuhabwa, P. Agostinis, B. Ahmed, W. Landuyt, B. Van Cleynenbreugel, H. Van Poppel and P. de Witte, Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder, *Photochem. Photobiol. Sci.*, 2004, **3**, 772–780.
- K. Gyuraszova, J. Mikes, A. Halaburkova, R. Jendzelovsky and P. Fedorocko, YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy, *Photochem. Photobiol. Sci.*, 2016, **15**, 812–821.
- J. T. Wessels, A.-C. Busse, M. Rave-Fraenk, S. Zaenker, R. Hermann, E. Grabbe and G.-A. Mueller, Photosensitizing and radiosensitizing effects of hypericin on human renal carcinoma cells *in vitro*, *Photochem. Photobiol.*, 2007, **84**, 228–235.
- P. Mauri and P. Pietta, High-performance liquid chromatography/electrospray mass spectrometry of *Hypericum perforatum* extracts, *Rapid Commun. Mass Spectrom.*, 2000, **14**, 95–99.
- H. Brockmann, F. Kluge and H. Muxfeldt, Total synthesis of hypericin, *Chem. Ber.*, 1957, **90**, 2302–2318.
- J. Banville and P. Brassard, Reactions of ketene acetals. 8. Simple syntheses of the methyl ester-ethers of the anthraquinones endocrocin, ptilometric acid, and clavorubin, *J. Org. Chem.*, 1976, **41**, 3018–3020.
- Y. Hirose, M. Kuroiwa, H. Yamashita, T. Tanaka and T. Megumi, Chemical studies on the natural anthraquinones. I. Syntheses of munjistin, emodin, and 3-hydroxy-2-methylanthraquinone, *Chem. Pharm. Bull.*, 1973, **21**, 2790–2793.
- J. Zhao, Z. Zhang, H. Chen and X. Chen, Studies on synthesis and anti-HIV RT activity of hypericin and ethylhypericin, *Yaoxue Xuebao*, 1998, **33**, 67–71.
- S. Aigner and H. Falk, A microwave-assisted synthesis of phenanthroperylene quinones as exemplified with hypericin, *Monatsh. Chem.*, 2008, **139**, 991–993.
- Y. Mazur, H. Bock and D. Lavie, *Preparation of Hypericin*, US Pat. 5120412A, 1992.
- L. Yip, J. B. Hudson, E. Gruszecka-Kowalik, L. H. Zalkow and T. G. H. Neil, Antiviral activity of a derivative of the photosensitive compound hypericin, *Phytomedicine*, 1996, **3**, 185–190.
- M. Waser, Y. Popova, C. W. Klampfl and H. Falk, 9,12-Dibenzothiazolylhypericin and 10,11-Dibenzothiazolyl-10,11-Didemethylhypericin: Photochemical Properties of Hypericin Derivatives Depending on the Substitution Site, *Monatsh. Chem.*, 2005, **136**, 1791–1797.
- S. W. Kim, J. H. Park, S. D. Yang, M. G. Hur, Y.-S. Kim, J.-S. Chai, Y. S. Kim and K. H. Yu, Facile synthesis and



- radioiodine labeling of hypericin, *Bull. Korean Chem. Soc.*, 2004, **25**, 1147–1150.
- 21 D. Geisslmeir and H. Falk,  $\omega, \omega'$ -Appended nucleo-base derivatives of hypericin, *Monatsh. Chem.*, 2008, **139**, 1127–1136.
  - 22 H. Falk and T. N. H. Tran, Synthesis and properties of an  $\omega, \omega'$ -appended eighteen carbon chains hypericin derivative, *Monatsh. Chem.*, 1996, **127**, 717–723.
  - 23 H. Falk and G. Schoppel, A synthesis of emodin anthrone, *Monatsh. Chem.*, 1991, **122**, 739–744.
  - 24 H. J. Banks, D. W. Cameron and W. D. Raverty, Chemistry of Coccoidea. II. Condensed polycyclic pigments from two Australian pseudococcids (Hemiptera), *Aust. J. Chem.*, 1976, **29**, 1509–1521.
  - 25 H. Falk and G. Schoppel, On the Synthesis of Hypericin by Oxidative Trimethylemodin Anthrone and Emodin Anthrone Dimerization: Isohypericin, *Monatsh. Chem.*, 1992, **123**, 931–938.
  - 26 D. Spitzner, Synthesis of photohypericin from emodin, *Angew. Chem.*, 1977, **89**, 55–56.
  - 27 E. Gruszecka-Kowalik and L. H. Zalkow, An improved synthesis of hypericin and related compounds, *Org. Prep. Proced. Int.*, 2000, **32**, 57–61.
  - 28 J. Motoyoshiya, Y. Masue, Y. Nishi and H. Aoyama, Synthesis of hypericin *via* emodin anthrone derived from a two-fold Diels-Alder reaction of 1,4-benzoquinone, *Nat. Prod. Commun.*, 2007, **2**, 67–70.
  - 29 J. Berlanda, T. Kiesslich, V. Engelhardt, B. Krammer and K. Plaetzer, Comparative *in vitro* study on the characteristics of different photosensitizers employed in PDT, *J. Photochem. Photobiol., B*, 2010, **100**, 173–180.
  - 30 Y. D. Liu, X. L. Liu, Y. Xiao, F. M. Chen and F. N. Xiao, A multifunctional nanoplatform based on mesoporous silica nanoparticles for imaging-guided chemo/photodynamic synergetic therapy, *RSC Adv.*, 2017, **7**, 31133–31141.
  - 31 H. Fan, G. Yan, Z. Zhao, X. Hu, W. Zhang, H. Liu, X. Fu, T. Fu, X. Zhang and W. Tan, A smart photosensitizer-manganese dioxide nanosystem for enhanced photodynamic therapy by reducing glutathione levels in cancer cells, *Angew. Chem.*, 2016, **55**, 5477–5482.
  - 32 L. B. Meng, W. Zhang, D. Li, Y. Li, X. Y. Hu, L. Wang and G. Li, pH-Responsive supramolecular vesicles assembled by water-soluble pillar[5]arene and a BODIPY photosensitizer for chemo-photodynamic dual therapy, *Chem. Commun.*, 2015, **51**, 14381–14384.
  - 33 H. H. Fan, X. B. Zhang and Y. Lu, Recent advances in DNzyme-based gene silencing, *Sci. China: Chem.*, 2017, **60**, 591–601.
  - 34 H.-M. Meng, H. Liu, H. Kuai, R. Peng, L. Mo and X.-B. Zhang, Aptamer-integrated DNA nanostructures for biosensing, bioimaging and cancer therapy, *Chem. Soc. Rev.*, 2016, **45**, 2583–2602.
  - 35 M. C. Montanha, L. L. Silva, F. B. B. Pangoni, G. B. Cesar, R. S. Goncalves, W. Caetano, N. Hioka, T. T. Tominaga, M. E. L. Consolaro, A. Diniz and E. Kimura, Response surface method optimization of a novel hypericin formulation in P123 micelles for colorectal cancer and antimicrobial photodynamic therapy, *J. Photochem. Photobiol., B*, 2017, **170**, 247–255.
  - 36 B. Kucharova, J. Mikes, R. Jendzelovsky, J. Vargova, L. Mikesova, Z. Jendzelovska, J. Koval and P. Fedorocko, Potentiation of hypericin-mediated photodynamic therapy cytotoxicity by MK-886: focus on ABC transporters, GDF-15 and redox status, *Photodiagn. Photodyn. Ther.*, 2015, **12**, 490–503.
  - 37 J. Mikes, R. Jendzelovsky and P. Fedorocko, in *Cellular aspects of photodynamic therapy with hypericin*, Nova Science Publishers, Inc., 2013, pp. 111–147.
  - 38 Y. Xu, D. Wang, Z. Zhuang, K. Jin, L. Zheng, Q. Yang and K. Guo, Hypericin-mediated photodynamic therapy induces apoptosis in K562 human leukemia cells through JNK pathway modulation, *Mol. Med. Rep.*, 2015, **12**, 6475–6482.
  - 39 M. Maslanakova, L. Balogova, P. Miskovsky, R. Tkacova and K. Stroffekova, Anti- and Pro-Apoptotic Bcl2 Proteins Distribution and Metabolic Profile in Human Coronary Aorta Endothelial Cells Before and After HypPDT, *Cell Biochem. Biophys.*, 2016, **74**, 435–447.
  - 40 A. M. Lima, C. D. Pizzol, F. B. F. Monteiro, T. B. Crezynski-Pasa, G. P. Andrade, A. O. Ribeiro and J. R. Perussi, Hypericin encapsulated in solid lipid nanoparticles: phototoxicity and photodynamic efficiency, *J. Photochem. Photobiol., B*, 2013, **125**, 146–154.
  - 41 D. Feinweber, T. Verwanger, O. Brueggemann, I. Teasdale and B. Krammer, Applicability of new degradable hypericin-polymer-conjugates as photosensitizers: principal mode of action demonstrated by *in vitro* models, *Photochem. Photobiol. Sci.*, 2014, **13**, 1607–1620.
  - 42 A. Kubin, F. Wierrani, U. Burner, G. Alth and W. Gruenberger, Hypericin – the facts about a controversial agent, *Curr. Pharm. Des.*, 2005, **11**, 233–253.
  - 43 P. Agostinis, A. Vantieghe, W. Merlevede and P. A. M. de Witte, Hypericin in cancer treatment: more light on the way, *Int. J. Biochem. Cell Biol.*, 2002, **34**, 221–241.
  - 44 L. M. Davids, B. Kleemann, S. Cooper and S. H. Kidson, Melanomas display increased cytoprotection to hypericin-mediated cytotoxicity through the induction of autophagy, *Cell Biol. Int.*, 2009, **33**, 1065–1072.
  - 45 G. Seitz, S. W. Warmann, S. Armeanu, H. Heitmann, P. Ruck, R. M. Hoffman, J. Fuchs and J. T. Wessels, *In vitro* photodynamic therapy of childhood rhabdomyosarcoma, *Int. J. Oncol.*, 2007, **30**, 615–620.
  - 46 J. Zuschrader, W. Schoefberger and H. Falk, A carbohydrate-linked hypericin photosensitizing agent, *Monatsh. Chem.*, 2008, **139**, 1387–1390.
  - 47 I. Teasdale, M. Waser, S. Wilfert, H. Falk and O. Brueggemann, Photoreactive, water-soluble conjugates of hypericin with polyphosphazenes, *Monatsh. Chem.*, 2012, **143**, 355–360.

